



Company Announcement no. 08/2008

To: OMX Nordic Exchange Copenhagen

Hørsholm, Denmark, March 14, 2008

LifeCycle Pharma A/S, Extraordinary General Meeting March 14, 2008 regarding change of authorisation for the Board of Directors to increase the Share Capital and Consideration and Approval of General Guidelines for Incentive Pay to the Members of the Board of Directors and Executive Management

Summary: On the general meeting the authorisation to the board of directors to increase the share capital was changed from nom. DKK 10,000,000 to nom. DKK 25,000,000 and General Guidelines for Incentive Pay to the Members of the Board of Directors and Executive Management were approved.

On 14 March 2008 an Extraordinary General Meeting was held in LifeCycle Pharma A/S, CVR-no. 26527767, at the address Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S.

The general meeting approved the proposal to change article 9 in the articles of association to the effect that the authorisation for the board of directors to increase the share capital was increased from nominal DKK 10,000,000 to nominal DKK 25,000,000.

Hereafter article 9 will be worded as follows:

"Article 9

The Board of Directors is in the period up until 1 July 2011 authorised, at one or more times, to increase the Company's share capital with up to nominal DKK 25,000,000.

Capital increases according to this authorisation can be carried out by the Board of Directors by way of contributions in kind (including e.g. take over of existing businesses), conversion of debt and/or cash capital contributions and can be carried out with or without pre-emptive subscription rights for the Company's shareholders at the discretion of the Board of Directors.

The new shares shall be negotiable shares issued to bearer, but may be recorded on name. The new shares shall not have any restrictions as to their transferability and no shareholder shall be obliged to have the shares redeemed fully or partly. The shares shall be with the same rights as the existing share capital on the date of the capital increase. The new shares shall give rights to dividends and other rights in the Company from the time which is determined by the Board of Directors in connection with the decision to increase the share capital."

LIFECYCLE PHARMA A/S	TEL. +45 7033 3300
KOGLE ALLÉ 4	FAX +45 3613 0319
DK-2970 HØRSHOLM	CVR. 26 52 77 67
WWW.LIFECYCLEPHARMA.COM	INFO@LCPHARMA.COM

page 1 of 2



The general meeting approved the board's proposal for general guidelines for incentive pay to the members of the board of directors and executive management.

A new article 19 to the Company's article of association was inserted with the following wording:

"Guidelines for incentive pay

§ 19

"On the general meeting held on March 14, 2008, the Company adopted general guidelines for incentive pay to the members of the board of directors and executive management."

Without undue delay after approval by the general meeting, the guidelines will also be made public on the Company's website (www.lcpharma.com) where it will also be stated that the guidelines were adopted on the general meeting held on March 14, 2008.

There were no further points for discussion.

About LifeCycle Pharma A/S ("LCP")

LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide™, currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.

For further information please contact LifeCycle Pharma A/S:

Flemming Ornskov, MD

or:

President and CEO

Hans Christian Teisen

+45 2420 0368; FO@lcpharma.com

Senior Vice President & CFO

+45 20 30 69 85; E-mail: hct@lcpharma.com

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSHOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 2 of 2